HKEx gene sequencing the first shares of Beikang Medical listed

February 08, China's assisted reproductive gene testing innovation enterprise Beikang Medical (Suzhou Beikang Medical Co., Ltd.) was officially listed on the main board of the Hong Kong Stock Exchange, stock code: 2170. About 66.667 million shares were issued before the exercise of the over-allment rights, raising a total of about HK$1.82 billion and offering prices of HK$27.36 per share, which was 402.8 times oversubscribed, an increase of 17.14 per cent to a total market value of HK$8.414 billion as at the time of writing. The listing will be the first gene sequencing stock on the Hong Kong Stock Exchange, opening the door to the large-scale industrialization of three generations of IVF kits.According to the 2018 statistics of the Health and Wellness Commission, the average pregnancy success rate of IVF in China is less than 50%. The clinical difficulty of IVF is that the embryo can only be judged by morphology, and it is not possible to accurately confirm whether the embryo is healthy or normal at the genetic level. The PGT-A kit developed by Beikang Medical has filled the clinical gap in embryo genetic testing in China and has been approved for "Special Approval of National Innovative Medical Devices" products. In February 2020, Beikang Medical PPT-A kit completed a large-scale embryo clinical trial, which was approved for listing by the State Drug Administration, marking the beginning of the "documented" era of China's three-generation IVF genetic test kit. Since August 2020, PGT-A kits have been incorporated into the national mandatory pharmaceutical industry standards as Class III. (U.S. News Agency)